Alexandro Gianforcaro1, Michael Kurz2, Francis X Guyette3, Clifton W Callaway3, Jon C Rittenberger3, Jonathan Elmer4. 1. University of Pittsburgh School of Medicine, Pittsburgh, PA, United States. 2. Department of Emergency Medicine, University of Alabama, Birmingham, AL, United States. 3. Department of Emergency Medicine, University of Pittsburgh, Pittsburgh, PA, United States. 4. Department of Emergency Medicine, University of Pittsburgh, Pittsburgh, PA, United States; Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh PA, United States. Electronic address: elmerjp@upmc.edu.
Abstract
BACKGROUND: Cessation of blood flow during out-of-hospital cardiac arrest (OHCA) results in microvascular thrombosis, protracted hypoperfusion after return of spontaneous circulation and damage to vital organs. We tested the hypothesis that pre-arrest antiplatelet and anticoagulant medication use would be associated with less post-arrest organ dysfunction and better outcomes. METHODS: We included OHCA patients treated from January 2005 to October 2014 at a single academic medical center. We combined our prospective OHCA registry of clinical and demographic data with a structured chart review to abstract home antiplatelet and anticoagulant medications. We fit unadjusted and adjusted regression models to test the association of antiplatelet and anticoagulant medication use with early post-arrest illness severity, survival and functionally favorable recovery. RESULTS: Of 1054 subjects, 295 (28%) were prescribed an antiplatelet agent and 147 (14%) were prescribed an anticoagulant prior to arrest. In adjusted models, antiplatelet agents were associated with lower post-arrest illness severity (adjusted OR 0.50 95% CI 0.33-0.77), greater odds of survival to discharge (adjusted OR 1.74 95% CI 1.08-2.80) and greater odds favorable functional outcome (adjusted OR 2.11 95% CI 1.17-3.79). By contrast, anticoagulation via any agent was not associated with illness severity, survival to discharge or favorable outcome. CONCLUSION: Preventing intra-arrest and post-arrest microvascular thrombosis via antiplatelet agents could represent a novel therapeutic target to improve outcomes after OHCA.
BACKGROUND: Cessation of blood flow during out-of-hospital cardiac arrest (OHCA) results in microvascular thrombosis, protracted hypoperfusion after return of spontaneous circulation and damage to vital organs. We tested the hypothesis that pre-arrest antiplatelet and anticoagulant medication use would be associated with less post-arrest organ dysfunction and better outcomes. METHODS: We included OHCA patients treated from January 2005 to October 2014 at a single academic medical center. We combined our prospective OHCA registry of clinical and demographic data with a structured chart review to abstract home antiplatelet and anticoagulant medications. We fit unadjusted and adjusted regression models to test the association of antiplatelet and anticoagulant medication use with early post-arrest illness severity, survival and functionally favorable recovery. RESULTS: Of 1054 subjects, 295 (28%) were prescribed an antiplatelet agent and 147 (14%) were prescribed an anticoagulant prior to arrest. In adjusted models, antiplatelet agents were associated with lower post-arrest illness severity (adjusted OR 0.50 95% CI 0.33-0.77), greater odds of survival to discharge (adjusted OR 1.74 95% CI 1.08-2.80) and greater odds favorable functional outcome (adjusted OR 2.11 95% CI 1.17-3.79). By contrast, anticoagulation via any agent was not associated with illness severity, survival to discharge or favorable outcome. CONCLUSION: Preventing intra-arrest and post-arrest microvascular thrombosis via antiplatelet agents could represent a novel therapeutic target to improve outcomes after OHCA.
Authors: R O Cummins; D A Chamberlain; N S Abramson; M Allen; P J Baskett; L Becker; L Bossaert; H H Delooz; W F Dick; M S Eisenberg Journal: Circulation Date: 1991-08 Impact factor: 29.690
Authors: Max Nieuwdorp; Timon W van Haeften; Mirella C L G Gouverneur; Hans L Mooij; Miriam H P van Lieshout; Marcel Levi; Joost C M Meijers; Frits Holleman; Joost B L Hoekstra; Hans Vink; John J P Kastelein; Erik S G Stroes Journal: Diabetes Date: 2006-02 Impact factor: 9.461
Authors: Jon C Rittenberger; Francis X Guyette; Samuel A Tisherman; Michael A DeVita; Rene J Alvarez; Clifton W Callaway Journal: Resuscitation Date: 2008-11 Impact factor: 5.262
Authors: Jonathan Elmer; Cesar Torres; Tom P Aufderheide; Michael A Austin; Clifton W Callaway; Eyal Golan; Heather Herren; Jamie Jasti; Peter J Kudenchuk; Damon C Scales; Dion Stub; Derek K Richardson; Dana M Zive Journal: Resuscitation Date: 2016-02-03 Impact factor: 5.262
Authors: Jerry P Nolan; Claudio Sandroni; Bernd W Böttiger; Alain Cariou; Tobias Cronberg; Hans Friberg; Cornelia Genbrugge; Kirstie Haywood; Gisela Lilja; Véronique R M Moulaert; Nikolaos Nikolaou; Theresa Mariero Olasveengen; Markus B Skrifvars; Fabio Taccone; Jasmeet Soar Journal: Intensive Care Med Date: 2021-03-25 Impact factor: 17.440